INBX
Inhibrx Biosciences, Inc.
Price Chart
Latest Quote
$82.23
Current Price| Previous Close | $76.27 |
| Open | $76.04 |
| Day High | $84.05 |
| Day Low | $76.04 |
| Volume | 201,341 |
Stock Information
| Shares Outstanding | 14.54M |
| Total Debt | $106.91M |
| Cash Equivalents | $153.09M |
| Revenue | $1.40M |
| Net Income | $-155.09M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.20B |
| EPS (TTM) | $-11.96 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 29/42| Debt to Equity | 0.06 |
| Debt to Earnings | 0.00 |
| Current Ratio | 3.94 |
| Quick Ratio | 3.76 |
| Avg Revenue Growth | -28.21% |
| Profit Margin | 843786.00% |
| Return on Equity | 1263.30% |
| Avg FCF Growth | 38.44% |
| FCF Yield | -16.47% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $82.23 | 201,341 |
| 2026-01-30 | $76.27 | 291,700 |
| 2026-01-29 | $72.56 | 297,500 |
| 2026-01-28 | $73.98 | 475,300 |
| 2026-01-27 | $73.49 | 146,800 |
| 2026-01-26 | $72.00 | 183,800 |
| 2026-01-23 | $74.66 | 122,100 |
| 2026-01-22 | $79.49 | 303,900 |
| 2026-01-21 | $75.10 | 146,700 |
| 2026-01-20 | $72.90 | 233,600 |
| 2026-01-16 | $72.27 | 252,800 |
| 2026-01-15 | $71.80 | 137,400 |
| 2026-01-14 | $75.93 | 116,700 |
| 2026-01-13 | $73.28 | 224,300 |
| 2026-01-12 | $75.94 | 200,200 |
| 2026-01-09 | $72.86 | 119,600 |
| 2026-01-08 | $75.20 | 147,600 |
| 2026-01-07 | $75.93 | 152,400 |
| 2026-01-06 | $76.10 | 202,400 |
| 2026-01-05 | $76.88 | 156,700 |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
📰 Latest News
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts
Insider Monkey • 2025-12-28T15:05:33Z
Inhibrx (INBX): Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates
Simply Wall St. • 2025-12-18T14:28:34Z
Evaluating Inhibrx Biosciences (INBX) Valuation Following Breakthrough Phase 2 Results for Ozekibart
Simply Wall St. • 2025-10-26T16:10:40Z
Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory
Clinical Trials Arena • 2025-10-24T11:40:16Z
Inhibrx shares surge after bone cancer drug slows disease progression in trial
Reuters • 2025-10-23T22:41:18ZOwning 45% shares,institutional owners seem interested in Inhibrx Biosciences, Inc. (NASDAQ:INBX),
Simply Wall St. • 2025-10-11T12:43:41Z
Insiders See US$5.42m Investment In Inhibrx Biosciences Jump Last Week
Simply Wall St. • 2025-08-15T11:25:09Z
Ligand Pharmaceuticals Stock Earns 84 RS Rating
Investor's Business Daily • 2025-07-17T18:05:32Z
Liquidia Stock Gets Relative Strength Rating Lift
Investor's Business Daily • 2025-07-15T17:08:04Z
Arcutis Biotherapeutics Stock Scores RS Rating Upgrade
Investor's Business Daily • 2025-07-10T18:24:49Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $200,000 | $1,800,000 | $1,301,000 |
| Operating Revenue | $200,000 | $1,800,000 | $1,301,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Interest Expense | $13,491,000 | $31,840,000 | - |
| Total Expenses | $331,648,000 | $221,021,000 | $116,624,000 |
| Other Income Expense | $2,021,573,000 | $-580,000 | $1,000 |
| Other Non Operating Income Expenses | $75,000 | $-580,000 | $1,000 |
| Net Non Operating Interest Income Expense | $-2,551,000 | $-19,923,000 | - |
| Interest Expense Non Operating | $13,491,000 | $31,840,000 | - |
| Operating Expense | $331,648,000 | $221,021,000 | $116,624,000 |
| General And Administrative Expense | $127,905,000 | $29,381,000 | $15,035,000 |
| Other Operating Expenses | - | - | $-14,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Interest Income | $-2,551,000 | $-19,923,000 | - |
| Interest Income | $10,940,000 | $11,917,000 | - |
| Normalized Income | $-333,923,604 | $-241,361,000 | $-115,325,000 |
| Net Income From Continuing And Discontinued Operation | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Total Operating Income As Reported | $-331,448,000 | $-219,221,000 | $-115,323,000 |
| Net Income Common Stockholders | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Income | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Income Including Noncontrolling Interests | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Net Income Continuous Operations | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $-1,634,000 | $0 |
| Pretax Income | $1,687,574,000 | $-239,724,000 | $-115,322,000 |
| Special Income Charges | $2,021,498,000 | $0 | - |
| Interest Income Non Operating | $10,940,000 | $11,917,000 | - |
| Operating Income | $-331,448,000 | $-219,221,000 | $-115,323,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Diluted EPS | $112.62 | $-16.95 | $-8.10 |
| Basic EPS | $114.01 | $-16.95 | $-8.10 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Tax Effect Of Unusual Items | $2,396 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-318,148,000 | $-206,693,000 | $-114,098,000 |
| Total Unusual Items | $2,021,498,000 | $0 | - |
| Total Unusual Items Excluding Goodwill | $2,021,498,000 | $0 | - |
| Reconciled Depreciation | $2,285,000 | $1,191,000 | $1,225,000 |
| EBITDA (Bullshit earnings) | $1,703,350,000 | $-206,693,000 | $-114,098,000 |
| EBIT | $1,701,065,000 | $-207,884,000 | $-115,323,000 |
| Diluted Average Shares | $14,984,000 | $14,241,175 | $14,241,175 |
| Basic Average Shares | $14,802,000 | $14,241,175 | $14,241,175 |
| Diluted NI Availto Com Stockholders | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Tax Provision | $2,000 | $3,000 | $3,000 |
| Restructuring And Mergern Acquisition | $-2,021,498,000 | $0 | - |
| Research And Development | $203,743,000 | $191,640,000 | $101,603,000 |
| Selling General And Administration | $127,905,000 | $29,381,000 | $15,035,000 |
| Other Gand A | $127,905,000 | $29,381,000 | $15,035,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Net Tangible Assets | $133,584,000 | $43,503,000 | $-7,300,000 |
| Total Assets | $180,767,000 | $307,893,000 | $16,645,000 |
| Total Non Current Assets | $20,369,000 | $12,535,000 | $10,382,000 |
| Other Non Current Assets | $6,831,000 | $3,164,000 | $3,164,000 |
| Current Assets | $160,398,000 | $295,358,000 | $6,263,000 |
| Other Current Assets | $816,000 | $728,000 | $674,000 |
| Prepaid Assets | $6,566,000 | $15,928,000 | $5,332,000 |
| Receivables | $420,000 | $778,000 | $257,000 |
| Accounts Receivable | $397,000 | $778,000 | $243,000 |
| Cash Cash Equivalents And Short Term Investments | $152,596,000 | $277,924,000 | - |
| Cash And Cash Equivalents | $152,596,000 | $277,924,000 | - |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Debt | $8,048,000 | $210,141,000 | $5,033,000 |
| Long Term Debt And Capital Lease Obligation | $6,453,000 | $208,078,000 | $3,173,000 |
| Current Debt And Capital Lease Obligation | $1,595,000 | $2,063,000 | $1,860,000 |
| Long Term Debt | - | $206,968,000 | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Liabilities Net Minority Interest | $47,183,000 | $264,390,000 | $23,945,000 |
| Total Non Current Liabilities Net Minority Interest | $6,453,000 | $208,078,000 | $3,173,000 |
| Current Liabilities | $40,730,000 | $56,312,000 | $20,772,000 |
| Payables And Accrued Expenses | $31,409,000 | $47,743,000 | $15,538,000 |
| Interest Payable | $0 | $2,348,000 | - |
| Payables | $9,245,000 | $10,954,000 | $4,343,000 |
| Accounts Payable | $9,245,000 | $10,954,000 | $4,343,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Common Stock Equity | $133,584,000 | $43,503,000 | $-7,300,000 |
| Total Equity Gross Minority Interest | $133,584,000 | $43,503,000 | $-7,300,000 |
| Stockholders Equity | $133,584,000 | $43,503,000 | $-7,300,000 |
| Retained Earnings | $-106,132,000 | $-613,734,000 | - |
| Other Equity Interest | - | $-7,973,000 | $-7,300,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Ordinary Shares Number | $14,475,904 | $14,241,175 | $14,241,175 |
| Share Issued | $14,475,904 | $14,241,175 | $14,241,175 |
| Tangible Book Value | $133,584,000 | $43,503,000 | $-7,300,000 |
| Invested Capital | $133,584,000 | $250,471,000 | $-7,300,000 |
| Working Capital | $119,668,000 | $239,046,000 | $-14,509,000 |
| Capital Lease Obligations | $8,048,000 | $3,173,000 | $5,033,000 |
| Total Capitalization | $133,584,000 | $250,471,000 | $-7,300,000 |
| Additional Paid In Capital | $239,715,000 | $657,232,000 | - |
| Capital Stock | $1,000 | $5,000 | - |
| Common Stock | $1,000 | $5,000 | - |
| Preferred Stock | $0 | $0 | - |
| Long Term Capital Lease Obligation | $6,453,000 | $1,110,000 | $3,173,000 |
| Current Capital Lease Obligation | $1,595,000 | $2,063,000 | $1,860,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,726,000 | $6,506,000 | $3,374,000 |
| Current Accrued Expenses | $22,164,000 | $36,789,000 | $11,195,000 |
| Net PPE | $13,538,000 | $9,371,000 | $7,218,000 |
| Accumulated Depreciation | $-8,893,000 | $-6,687,000 | $-5,540,000 |
| Gross PPE | $22,431,000 | $16,058,000 | $12,758,000 |
| Leases | $795,000 | $441,000 | $441,000 |
| Construction In Progress | $0 | $3,592,000 | $0 |
| Other Properties | $7,338,000 | $2,952,000 | $4,717,000 |
| Machinery Furniture Equipment | $14,298,000 | $9,073,000 | $7,600,000 |
| Properties | $0 | $0 | $0 |
| Duefrom Related Parties Current | $23,000 | $0 | $14,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Free Cash Flow | $-197,006,000 | $-197,902,000 | $-91,497,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Operating Cash Flow | $-194,409,000 | $-193,309,000 | $-90,811,000 |
| Cash Flow From Continuing Operating Activities | $-194,409,000 | $-193,309,000 | $-90,811,000 |
| Operating Gains Losses | $-1,998,797,000 | $1,637,000 | $19,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Capital Expenditure | $-2,597,000 | $-4,593,000 | $-686,000 |
| Investing Cash Flow | $-2,597,000 | $-4,593,000 | $-686,000 |
| Cash Flow From Continuing Investing Activities | $-2,597,000 | $-4,593,000 | $-686,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Issuance Of Capital Stock | $0 | $200,000,000 | - |
| Financing Cash Flow | $71,678,000 | $201,961,000 | $91,497,000 |
| Cash Flow From Continuing Financing Activities | $71,678,000 | $201,961,000 | $91,497,000 |
| Net Common Stock Issuance | $0 | $200,000,000 | - |
| Common Stock Issuance | $0 | $200,000,000 | - |
| Net Other Financing Charges | - | $-355,000 | $91,497,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Interest Paid Supplemental Data | $11,506,000 | $26,717,000 | - |
| Income Tax Paid Supplemental Data | $2,000 | $3,000 | $4,000 |
| End Cash Position | $152,596,000 | $277,924,000 | $0 |
| Beginning Cash Position | $277,924,000 | $273,865,000 | $0 |
| Changes In Cash | $-125,328,000 | $4,059,000 | - |
| Proceeds From Stock Option Exercised | $71,678,000 | $2,316,000 | - |
| Net PPE Purchase And Sale | $-2,597,000 | $-4,593,000 | $-686,000 |
| Purchase Of PPE | $-2,597,000 | $-4,593,000 | $-686,000 |
| Change In Working Capital | $52,051,000 | $15,348,000 | $3,858,000 |
| Change In Other Current Liabilities | $-1,408,000 | $-1,860,000 | $-1,674,000 |
| Change In Other Current Assets | $-3,667,000 | $0 | $-1,317,000 |
| Change In Payables And Accrued Expense | $53,786,000 | $28,180,000 | $6,923,000 |
| Change In Accrued Expense | $35,883,000 | $26,071,000 | $7,301,000 |
| Change In Payable | $17,903,000 | $2,109,000 | $-378,000 |
| Change In Account Payable | $17,903,000 | $2,109,000 | $-378,000 |
| Change In Prepaid Assets | $2,982,000 | $-10,285,000 | $407,000 |
| Change In Receivables | $358,000 | $-521,000 | $621,000 |
| Changes In Account Receivables | $381,000 | $-535,000 | $130,000 |
| Other Non Cash Items | $3,962,000 | $5,030,000 | $1,621,000 |
| Stock Based Compensation | $58,518,000 | $24,846,000 | $17,791,000 |
| Depreciation Amortization Depletion | $2,285,000 | $1,191,000 | $1,225,000 |
| Depreciation And Amortization | $2,285,000 | $1,191,000 | $1,225,000 |
| Earnings Losses From Equity Investments | $0 | $1,634,000 | $0 |
| Gain Loss On Sale Of PPE | $12,000 | $3,000 | $19,000 |
| Gain Loss On Sale Of Business | $-1,998,809,000 | $0 | - |
| Net Income From Continuing Operations | $1,687,572,000 | $-241,361,000 | $-115,325,000 |
| Change In Other Working Capital | - | $-166,000 | $-1,102,000 |